PUBLISHER: Allied Market Research | PRODUCT CODE: 1365752
PUBLISHER: Allied Market Research | PRODUCT CODE: 1365752
According to a new report published by Allied Market Research, titled, "Constipation Treatment Market," The constipation treatment market was valued at $5.9 billion in 2022, and is estimated to reach $10.1 billion by 2032, growing at a CAGR of 5.6% from 2023 to 2032.
The constipation treatment market growth is driven by high presence of market players who manufacture constipation treatment products, rise in prevalence of constipation, and increase in use of opioids for pain management. The well-known side effects of opioids are their impact on the gastrointestinal system, often causing constipation. This effect occurs due to the way opioids interact with receptors in the gastrointestinal tract and the nervous system. Thus, rise in population suffering from chronic pain is anticipated to drive the use of pain killers. Therefore, this factor is anticipated to increase in prevalence of constipation and boost the growth of market. For instance, according to U.S. Chronic Pain Foundation, in 2022, 50 million Americans live with chronic pain, or pain that lasts most days or every day for three months or more. More than half (52%) said their average pain level is 7 or more on a scale of 1-10.
Moreover, rising incidence of constipation, often linked to sedentary lifestyles, poor dietary habits, and stress, is a primary driver for the growth of the constipation treatment market. Changes in dietary habits, including a shift toward processed foods with lower fiber content, can contribute to constipation. This drives the demand for treatments to alleviate its symptoms. In addition, stress and mental health issues can impact digestive processes, including bowel movements. Thus, unhealthy lifestyle factors are anticipated to increase in prevalence of constipation and drive the growth of market.
In addition, rise in number of geriatric populations is anticipated to drive the growth of the constipation treatment market. As people age, the digestive system tends to slow down, including the movement of food and waste through the intestines. This slower transit time can lead to the accumulation of stool in the colon and contribute to constipation. Thus, rise in number of geriatric populations is anticipated to increase in prevalence of constipation. For instance, according to World Health Organization (WHO), it was estimated that, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time, the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million. Moreover, according to Frontiers in Public Health, in 2022, it was reported that, the prevalence of constipation was 17.60% in elderly people aged 65 years and old.
The constipation treatment market is segmented based on product type, disease type, prescription type, distribution channel, and region. By product type, the market is classified into Mu-opioid receptor antagonists, laxative, chloride channel-2 activator, guanylate cyclase-C (GC-C) agonist, and others. Others includes selective 5-ht agonists and sodium-proton-exchanger subtype 3 (NHE3) inhibitor. As per disease type, the constipation treatment market is segmented into opioid-induced constipation, chronic idiopathic constipation, and irritable bowel syndrome with constipation. According to prescription type, the market is classified into prescribed drugs and over-the-counter drugs. By distribution channel, the market is divided into online pharmacy, drug store & retail pharmacy and others. Others includes hospital pharmacies and general stores.
Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Major key players that operate in the global constipation treatment market are Salix Pharma (Bausch Health), Takeda Pharmaceutical, AbbVie, Abbott, Sanofi, Bayer AG, AstraZeneca plc., Ironwood Pharmaceuticals, Inc., Prestige Consumer Healthcare Inc. and Ardelyx. Key players operating in the market have adopted product approval, product launch, acquisition, and agreement as their key strategies to expand their constipation treatment market share.
Additional benefits you will get with this purchase are:
Possible Customization with this report (with additional cost and timeline talk to the sales executive to know more)